


FIGURE 1

Figure 1A


HLA-A2/BMLF1 tetramer



- A2.10 BM/A2
- A4.5 BM/A2
- LP16 IE1/A2
- ◇— LP23 IE1/A2
- ▽— Melan-A/A2
- ◇— BZ/B18
- \*— BZ/B14
- ⊙— Tyrosinase/B35
- ⊠— 22.19 BZ/B40

Figure 1B

Mutated HLA-A2/BMLF1 tetramer



WO 01/18053

PCV/FR00/02443

1/1

FIGURE 2

HLA-A2/pp65 TETRAMERS




Figure 2A


Figure 2B

WO 01/18053

PCT/FR00/02443


3/7

FIGURE 3




47


FIGURE 4A



**FIGURE 4B**



**FIGURE 4C**



**Ratio of mutated tetramer AFI/CD3 AFI**

**A2.10: 0,43**

**A4.5: 0,47**


09/831019

WO 01/16053

PCT/FR00/02443

FIGURE 5

57




WO 01/18053

PCT/FR00/02443


Marking before screening

6/7


FIGURE 6



Marking after screening with normal A2/pp65 tetramer



Marking after screening with mutated A2/pp65 tetramer




WO 01/18053

PCT/FR00/02443

7/7

FIGURE 7

Patient 1Patient 2